[go: up one dir, main page]

MA27100A1 - Forme posologique orale contenant un inhibiteur de type 4 de pde en tant qu'ingredient actif et du polyvinylpyrrolidone en tant qu'excipient - Google Patents

Forme posologique orale contenant un inhibiteur de type 4 de pde en tant qu'ingredient actif et du polyvinylpyrrolidone en tant qu'excipient

Info

Publication number
MA27100A1
MA27100A1 MA27774A MA27774A MA27100A1 MA 27100 A1 MA27100 A1 MA 27100A1 MA 27774 A MA27774 A MA 27774A MA 27774 A MA27774 A MA 27774A MA 27100 A1 MA27100 A1 MA 27100A1
Authority
MA
Morocco
Prior art keywords
pde
inhibitor
polyvinylpyrrolidone
excipient
active ingredient
Prior art date
Application number
MA27774A
Other languages
English (en)
Inventor
Rango Dietrich
Klaus Eistetter
Hartmut Ney
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27758398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002107160 external-priority patent/DE10207160A1/de
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MA27100A1 publication Critical patent/MA27100A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
MA27774A 2002-02-20 2004-07-09 Forme posologique orale contenant un inhibiteur de type 4 de pde en tant qu'ingredient actif et du polyvinylpyrrolidone en tant qu'excipient MA27100A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002107160 DE10207160A1 (de) 2002-02-20 2002-02-20 Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
EP02003811 2002-02-20

Publications (1)

Publication Number Publication Date
MA27100A1 true MA27100A1 (fr) 2004-12-20

Family

ID=27758398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27774A MA27100A1 (fr) 2002-02-20 2004-07-09 Forme posologique orale contenant un inhibiteur de type 4 de pde en tant qu'ingredient actif et du polyvinylpyrrolidone en tant qu'excipient

Country Status (33)

Country Link
US (11) US7951397B2 (fr)
EP (2) EP2258394B1 (fr)
JP (1) JP4163120B2 (fr)
KR (2) KR101386843B1 (fr)
CN (2) CN102764242B (fr)
AR (1) AR038527A1 (fr)
AT (1) ATE550038T1 (fr)
AU (1) AU2003206924B2 (fr)
BR (1) BR0307739A (fr)
CA (1) CA2475923C (fr)
CY (2) CY1112811T1 (fr)
DK (2) DK1478399T3 (fr)
EA (1) EA008219B1 (fr)
EC (1) ECSP045238A (fr)
ES (2) ES2384378T3 (fr)
GE (1) GEP20074079B (fr)
IL (3) IL162843A0 (fr)
IS (1) IS7410A (fr)
MA (1) MA27100A1 (fr)
ME (1) ME00566A (fr)
MX (1) MXPA04005759A (fr)
MY (1) MY140561A (fr)
NO (1) NO332844B1 (fr)
NZ (1) NZ535197A (fr)
PE (1) PE20030823A1 (fr)
PL (1) PL226401B1 (fr)
PT (2) PT1478399E (fr)
RS (1) RS52548B (fr)
SI (2) SI1478399T1 (fr)
TN (1) TNSN04124A1 (fr)
TW (1) TWI363636B (fr)
UA (1) UA84266C2 (fr)
WO (1) WO2003070279A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
BRPI0406427B8 (pt) 2003-03-10 2021-05-25 Astrazeneca Ab processo para a preparação de roflumilast
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
CN1791429A (zh) 2003-05-22 2006-06-21 奥坦纳医药公司 包含pde4抑制剂和pde5抑制剂的组合物
DE10350528A1 (de) * 2003-10-29 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
WO2006097456A1 (fr) * 2005-03-16 2006-09-21 Nycomed Gmbh Forme posologique a gout masque
NZ561746A (en) 2005-04-19 2011-09-30 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
BRPI0713768A2 (pt) 2006-07-05 2012-10-30 Nycomed Gmbh combinação de inibidores de reductase de hmg-coa com inibidores de fosfodiesterase 4 para o tratamento de doenças pulmonares inflamatórias
WO2008093221A2 (fr) * 2007-02-01 2008-08-07 Glenmark Pharmaceuticals, S.A. Compositions pharmaceutiques pour le traitement de troubles inflammatoires et allergiques
ES2644803T5 (es) 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
EP2140861A1 (fr) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Formule de dosage pharmaceutique comportant une composition de porteur polymérique
EP2186521A1 (fr) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositions pour le traitement et la prévention des maladies comportant des pathogènes bactériennes, virales et fongiques et fragments associés au polyvinylpyrrolidone et/ou polyvinylpolypyrrolidone en tant que composant actif
CA2793525C (fr) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Procede d'amelioration de la dissolution d'un agent anticoagulant
WO2012053704A1 (fr) 2010-10-22 2012-04-26 대우조선해양 주식회사 Récipient de stockage destiné à un gaz naturel liquéfié
SMT201700099T1 (it) 2011-02-07 2017-03-08 Scipharm Sarl Nuova composizione per il trattamento di fibrosi cistica
BR112014002397B1 (pt) 2011-08-10 2021-08-03 Daiichi Sankyo Company, Limited Formulação sólida na forma de tablete ou cápsula contendo derivado de diamida
CN102274222B (zh) * 2011-08-18 2013-04-10 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特药物组合物及其制备方法
WO2013030789A1 (fr) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Forme pharmaceutique orale solide contenant un inhibiteur pde-iv faiblement soluble dans l'eau
FI3756650T3 (fi) * 2011-12-27 2025-10-30 Amgen Europe Gmbh (+)-2-[1-(3-etoksi-4-metoksifenyyli)-2-metaanisulfonyylietyyli]-4-asetyyliaminoisoindoliini-1,3-dionin formulaatioita
CN103446070B (zh) * 2012-05-31 2016-06-22 天津康鸿医药科技发展有限公司 一种罗氟司特固体速释制剂及其制备方法
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
CN103565806A (zh) * 2012-07-31 2014-02-12 江苏柯菲平医药有限公司 一种罗氟司特口服制剂及其制备方法
AU2013312981B2 (en) * 2012-09-06 2017-06-22 Mcpharma Biotech Inc. Treatment of diarrhea and post-weaning diarrhea with resistant potato starch
CN102871976A (zh) * 2012-09-29 2013-01-16 华润赛科药业有限责任公司 一种含有罗氟司特作为活性成分的片剂及其制备方法
CN102949370B (zh) * 2012-11-27 2018-05-04 贵州信邦制药股份有限公司 一种罗氟司特片及其制备方法和检测方法
CN103127011B (zh) * 2012-12-27 2014-11-26 深圳万乐药业有限公司 罗氟司特片及其制备方法
CN103330689A (zh) * 2013-03-31 2013-10-02 北京万全德众医药生物技术有限公司 一种含有罗氟司特的口腔崩解片
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
EP3043798A4 (fr) * 2013-09-13 2017-04-12 Hetero Research Foundation Compositions pharmaceutiques de roflumilast et leur procédé de préparation
WO2015132708A1 (fr) * 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Composition pharmaceutique de roflumilast
EP3174999A1 (fr) 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Diagnostic différentiel et choix de thérapie pour la polyarthrite rhumatoïde et l'arthrite psoriasique
ES2777550T3 (es) 2014-10-24 2020-08-05 Hisamitsu Pharmaceutical Co Profármaco de roflumilast
WO2016120746A1 (fr) * 2015-01-29 2016-08-04 Micro Labs Limited Composition pharmaceutique comprenant du roflumilast
CN106176639A (zh) * 2015-04-30 2016-12-07 四川科伦药物研究院有限公司 一种制备罗氟司特片的方法
RU2659206C2 (ru) * 2016-04-14 2018-06-28 Общество с ограниченной ответственностью "Технофарм" Состав и способ промышленного производства тритурации дигоксина (варианты)
CN106139161A (zh) * 2016-08-12 2016-11-23 合肥久诺医药科技有限公司 一种罗氟司特包合物及其固体制剂
JP7019978B2 (ja) * 2017-06-30 2022-02-16 富士電機株式会社 設備管理システム、設備管理方法およびプログラム
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106754A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
CN111643470A (zh) * 2020-04-30 2020-09-11 山东希尔康泰药业有限公司 罗氟司特薄膜包衣片制备工艺
WO2022103634A1 (fr) 2020-11-16 2022-05-19 Orcosa Inc. Utilisation améliorée de cannabinoïdes dans le traitement de l'épilepsie
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
EP4586999A1 (fr) 2022-09-15 2025-07-23 Arcutis Biotherapeutics, Inc. Compositions pharmaceutiques de roflumilast et de solvants capables de dissoudre des quantités élevées de médicament
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4024240A (en) * 1975-07-18 1977-05-17 Eli Lilly And Company Antibiotic A-32390 compositions
US4343804A (en) * 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
NZ196700A (en) * 1980-04-18 1983-04-12 Smith & Nephew Ass Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives
DE3269604D1 (en) 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) * 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
DE3308239A1 (de) 1983-03-09 1984-09-13 Basf Ag, 6700 Ludwigshafen N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
GB8415540D0 (en) * 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
JPS61205208A (ja) 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の速溶性製剤
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS61205208U (fr) 1985-06-12 1986-12-24
JPS625966A (ja) * 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (fr) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Composés d'imidazopyridine et procédés pour leur préparation
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
JPH0249720Y2 (fr) 1986-05-08 1990-12-27
US5286494A (en) 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4791117A (en) 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
EP0266890A1 (fr) 1986-10-07 1988-05-11 Yamanouchi Pharmaceutical Co. Ltd. Dérivés d'imidazopyridine, leur production et compositions pharmaceutiques les contenant
EP0264883A3 (fr) * 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Dérivés de la pyridine substitués
US4831041A (en) * 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
CA1327796C (fr) 1987-07-16 1994-03-15 Jorg Senn-Bilfinger Diazoles
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US4900775A (en) 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5011843A (en) 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
EP0368158A1 (fr) 1988-11-07 1990-05-16 Byk Gulden Lomberg Chemische Fabrik GmbH Imidazopyridines
JPH02270873A (ja) 1989-03-13 1990-11-05 Fujisawa Pharmaceut Co Ltd イミダゾピリジン化合物およびその製造法
CA2011086A1 (fr) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, leur utilisation et medicaments les contenant
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
EP0393500A1 (fr) 1989-04-17 1990-10-24 Byk Gulden Lomberg Chemische Fabrik GmbH Arylpyridazines, leur préparation, leur utilisation et composés pharmaceutiques les contenant
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3943385A1 (de) 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
FR2657257B1 (fr) 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
KR920701162A (ko) * 1990-03-28 1992-08-11 오츠카 아끼히코 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
JP2851117B2 (ja) 1990-03-30 1999-01-27 日清製粉株式会社 インドール誘導体およびそれらを有効成分とする抗潰瘍薬
JP2816227B2 (ja) 1990-03-30 1998-10-27 日清製粉株式会社 抗潰瘍薬
AU7754691A (en) 1990-04-27 1991-11-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1992006979A1 (fr) 1990-10-15 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelles diazines
CA2094127A1 (fr) 1990-10-16 1992-04-17 Hermann Amschler Arylpyridazinones
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5935978A (en) 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
MX9200338A (es) 1991-01-29 1992-12-01 Smithkline Beecham Intercredit Sales de compuestos de quinolina y composiciones farmaceuticas que las contienen
SE9100920D0 (sv) * 1991-03-27 1991-03-27 Astra Ab New active compounds
WO1992019602A1 (fr) 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelles pyridazines
US5320848A (en) * 1991-05-28 1994-06-14 Affinity Biotech, Inc. Chewable drug-delivery composition
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
ATE179419T1 (de) 1991-10-25 1999-05-15 Byk Gulden Lomberg Chem Fab Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
US5262171A (en) * 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
GB9126438D0 (en) 1991-12-12 1992-02-12 Smithkline Beecham Intercredit New quinoline derivatives
SG43179A1 (en) 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
GB9200607D0 (en) 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201693D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
WO1993015045A1 (fr) 1992-01-29 1993-08-05 Smithkline Beecham Corporation Derives d'acide n-(3-phenylpropyle) oxamique, d'oxamate et d'oxamide
WO1993015044A1 (fr) 1992-01-29 1993-08-05 Smithkline Beecham Corporation Derives d'acide n-benzyloxamique, d'oxamate et d'oxamide et leur utilisation comme inhibiteurs du facteur de necrose tumorale (fnt) et de la phosphodiesterase iv (pde iv)
JP3523275B2 (ja) 1992-03-26 2004-04-26 東光薬品工業株式会社 貼付剤
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
EP0607373B1 (fr) 1992-06-15 1997-03-19 Celltech Therapeutics Limited Derives a groupe phenyle trisubstitue utilises comme inhibiteurs selectifs de la phosphodiesterase iv
PT652868E (pt) 1992-07-28 2005-01-31 Aventis Pharma Ltd Inibidores da fosfodiesterase do amp ciclico
US5891904A (en) 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) * 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2167362T3 (es) * 1993-04-22 2002-05-16 Byk Gulden Lomberg Chem Fab Sales de piridinio y su utilizacion para combatir a bacterias helicobacter.
DE4314963A1 (de) 1993-05-06 1994-11-10 Bayer Ag Substituierte Pyridine und 2-Oxo-1,2-dihydropyridine
US5556863A (en) 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
SI0706513T1 (en) * 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
EP0719561A4 (fr) 1993-08-10 1997-07-30 Fujisawa Pharmaceutical Co Preparation absorbable par voie percutanee
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (uk) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
US5559110A (en) * 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
SE9401197D0 (sv) 1994-04-11 1994-04-11 Astra Ab Active compounds
ZA954599B (en) 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
JPH10505333A (ja) 1994-07-28 1998-05-26 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング イミダゾピリジン−アゾリジノン
JP3031280B2 (ja) 1994-08-19 2000-04-10 東陶機器株式会社 便器洗浄装置
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
JPH0959152A (ja) 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
FR2746800B1 (fr) * 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
JP3031280U (ja) 1996-05-15 1996-11-22 サン トップ コンピューター システムズ コーポレーション 線性ｃｃｄバーコードの読取り装置
DE69738949D1 (de) 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
JP3554337B2 (ja) 1996-09-04 2004-08-18 ファイザー・インク インダゾール誘導体、およびホスホジエステラーゼ（ｐｄｅ）タイプ４と腫瘍壊死因子（ｔｎｆ）産生の阻害剤としてのインダゾール誘導体の使用
JP2001503766A (ja) 1996-11-12 2001-03-21 フアーマシア・アンド・アツプジヨン・アー・ベー 複数の多孔質セルロースマトリクス（ｐｃｍ）を含むコンパクト部材、その製造および使用方法
HU227520B1 (hu) 1997-02-17 2011-07-28 Nycomed Gmbh ARDS és IRDS kezelésére szolgáló, 3-(ciklopropil-metoxi)-N-(3,5-diklór-4-piridinil)-4-(difluor-metoxi)-benzamidot és tüdõfelületaktív anyagot tartalmazó kompozíció
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
WO1998042707A1 (fr) 1997-03-24 1998-10-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Composes de tetrahydropyrido
FR2762841B1 (fr) 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
CA2289542A1 (fr) * 1997-05-28 1998-12-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydropyrannes fondus
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
PT1037607E (pt) * 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
BR9910269A (pt) * 1998-05-07 2001-01-09 Corixa Corp Composição adjuvante e métodos para seu uso
WO1999063929A2 (fr) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Inhibiteurs multiliaison de proteine triglyceride transferase microsomique
CN1158996C (zh) 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
SE9802793D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802794D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
US6288118B1 (en) * 1998-08-26 2001-09-11 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
EP1109810B1 (fr) 1998-08-31 2004-06-16 ALTANA Pharma AG N-oxydes de benzonaphthyridine possedant une activite anti-pde3 et anti-pde4
SK285165B6 (sk) 1998-09-23 2006-07-07 Altana Pharma Ag Tetrahydropyridoétery, farmaceutický prostriedok s ich obsahom a ich použitie
EP1118615A4 (fr) 1998-09-29 2002-02-27 Fujisawa Pharmaceutical Co Nouveaux sels d'un compose de pyridopyrazine et cristaux desdits sels
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
CA2349476A1 (fr) * 1998-11-03 2000-05-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazonaphtyridines
DE19858331A1 (de) 1998-12-17 2000-06-21 Boehringer Ingelheim Pharma Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren
US6417190B1 (en) * 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
DK1161239T3 (da) 1999-03-10 2005-02-14 Altana Pharma Ag 3- cyclopropylmethoxy-4-difluormethoxy-N-(3,5-dichlorpyrid-4-yl)benzamid til behandling af dissemineret sklerose
CN1126468C (zh) 1999-04-08 2003-11-05 王力田 一种黑玉米秸秆饮料及其制备方法
AU3966600A (en) * 1999-04-17 2000-11-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Haloalkoxy imidazonaphthyridines
KR100328972B1 (ko) 1999-04-23 2002-03-20 서경배 피부 유용 활성성분을 함유한 화장료 또는 피부도포용 의약품 조성물의 제조방법 및 이러한 방법에 의해 제조된 화장료 또는 피부도포용 의약품 조성물
JP2002543133A (ja) * 1999-05-04 2002-12-17 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ロフルミラストおよびｐｄｅ−３インヒビターを含有する共力薬の組合せ物
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
UA74339C2 (uk) 1999-06-07 2005-12-15 Алтана Фарма Аг Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
DK1200090T3 (da) 1999-08-03 2013-11-25 Icos Corp Farmaceutisk formulering omfattende en beta-carbolin og dens anvendelse til behandling af seksuel dysfunktion
EP1671651B1 (fr) * 1999-08-21 2009-11-11 Nycomed GmbH Combinaison synergique de pumafentrine et salméterol
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
WO2001035236A1 (fr) 1999-10-25 2001-05-17 Sony Corporation Procede de gestion de donnees de contenu
US7076437B1 (en) 1999-10-29 2006-07-11 Victor Levy Process for consumer-directed diagnostic and health care information
CZ20021443A3 (cs) * 1999-10-29 2003-01-15 Smithkline Beecham Corporation Způsob podávání inhibitoru fosfodiesterázy 4
US6985188B1 (en) 1999-11-30 2006-01-10 Thomson Licensing Video decoding and channel acquisition system
US7250174B2 (en) * 1999-12-07 2007-07-31 Schott Ag Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PL357555A1 (en) 2000-01-31 2004-07-26 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
US6379682B1 (en) * 2000-02-07 2002-04-30 Color Access, Inc. Clear water-in-oil emulsions
US20030207845A1 (en) * 2001-02-08 2003-11-06 Keating Elizabeth T. Method and compositions for treating an inflammatory disease
EP1261331A4 (fr) 2000-02-16 2005-01-05 Univ Nebraska Medical Ct Procede et compositions permettant de traiter les maladies fibrosantes
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
JP2003534328A (ja) * 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
EP1161950A1 (fr) * 2000-06-09 2001-12-12 Warner-Lambert Company Utilisation de diazepinoindoles dans le traitement des bronchopneumonopathies chroniques obstructives
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
EP1199074A1 (fr) 2000-09-15 2002-04-24 Warner-Lambert Company Composition pharmaceutique pour la prévention ou le traitement de maladies associées à un excès de production d' IL-12
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CA2427814C (fr) 2000-11-07 2009-06-02 Merck & Co., Inc. Combinaison d'un inhibiteur de pde4 et d'un antagoniste des leucotrienes dans le traitement de troubles respiratoires et bronchiques
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
DK1341528T3 (da) 2000-12-07 2012-03-26 Nycomed Gmbh Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel
ES2403238T3 (es) 2000-12-07 2013-05-16 Takeda Gmbh Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
US7988999B2 (en) 2000-12-07 2011-08-02 Nycomed Gmbh Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
EP1366760B1 (fr) 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Comprimes a dissolution rapide dans la cavite buccale
CA2440069A1 (fr) 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Compositions pharmaceutiques au gout dissimule
FR2821745B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6702796B2 (en) 2001-03-26 2004-03-09 The Procter & Gamble Company Absorbent interlabial device having an improved tab
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
DE60216588T2 (de) 2001-05-25 2007-09-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
CN1471538A (zh) 2001-06-27 2004-01-28 前体生物药物股份有限公司 用于竞争性调节二肽基肽酶iv催化的肽结构
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6756392B2 (en) * 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
EP1478358B1 (fr) 2002-02-11 2013-07-03 Bayer HealthCare LLC Tosylate de sorafenib pour le traitement des maladies caractérisées par une angiogénèse anormale
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
BR0310061A (pt) 2002-05-16 2005-03-01 Pharmacia Corp Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
US20030215498A1 (en) 2002-05-17 2003-11-20 Harland Ronald S. Rapidly disintegrating comressed tablets comprising biologically active compounds
SI2020243T1 (sl) 2002-05-28 2018-11-30 Astrazeneca Ab Farmacevtski pripravek za topično uporabo
US20030235631A1 (en) 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
CA2800126A1 (fr) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Traitement de troubles en relation avec le tnf.alpha.
US20030018071A1 (en) * 2002-08-09 2003-01-23 Rennard Stephen I. Method and compositions for treating fibrotic diseases
CA2494613C (fr) 2002-08-10 2011-06-28 Altana Pharma Ag Piperidine-phthalazones a substitution pyrrolidinedione utilises comme inhibiteurs de la phosphodiesterase-4 (pde4)
ATE348616T1 (de) 2002-08-29 2007-01-15 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
RU2005109909A (ru) 2002-09-04 2006-10-10 Рэнбакси Лабораториз Лимитед (In) Лекарственные формы с замаскированным вкусом и способы их получения
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
CN100346777C (zh) * 2002-11-27 2007-11-07 奥坦纳医药公司 包括罗氟斯特和福莫特罗的新的协同组合
PL214869B1 (pl) * 2002-11-27 2013-09-30 Nycomed Gmbh Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol
EP1581197A1 (fr) 2002-12-11 2005-10-05 Ranbaxy Laboratories, Limited Composition pour enrobage de masquage de gout et procedes d'application de ladite composition
MXPA05008193A (es) 2003-01-30 2006-05-25 Ethypharm Sa Particulas con revestimiento que oculta el sabor, proceso para la preparacion de las mismas y tabletas orodispersables que contienen dichas particulas revestidas.
BRPI0406427B8 (pt) 2003-03-10 2021-05-25 Astrazeneca Ab processo para a preparação de roflumilast
MXPA05010160A (es) * 2003-03-28 2005-11-16 Altana Pharma Ag Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
CN1791429A (zh) 2003-05-22 2006-06-21 奥坦纳医药公司 包含pde4抑制剂和pde5抑制剂的组合物
US20050026883A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2007501810A (ja) * 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
EP1673064A1 (fr) 2003-08-28 2006-06-28 Sandoz AG Composition pharmaceutique contenant un anticonvulsivant dote d'un enrobage masquant le gout
WO2005026095A1 (fr) 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Procede de preparation de roflumilast
EP1677778A2 (fr) 2003-10-09 2006-07-12 Inverseon, Inc. Methode de traitement de maladies des voies respiratoires faisant appel a des agonistes inverses beta-adrenergiques
MXPA06004499A (es) 2003-10-21 2006-06-27 Pharmacia Corp Metodo para el tratamiento o la prevencion de inflamacion respiratoria con un inhibidor de ciclooxigenasa 2 en combinacion con un inhibidor de fosfodiesterasa 4 y sus composiciones.
WO2005058892A1 (fr) 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
US20070254928A1 (en) * 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US7562356B2 (en) * 2004-09-22 2009-07-14 Hewlett-Packard Development Company, L.P. Automatically resolving patch dependencies for a path bundle
US7884059B2 (en) * 2004-10-20 2011-02-08 Afton Chemical Corporation Oil-soluble molybdenum derivatives derived from hydroxyethyl-substituted Mannich bases
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006094640A2 (fr) 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Association de roflumilast et d'un inhibiteur de l'integrine, et procede de traitement
WO2006097456A1 (fr) * 2005-03-16 2006-09-21 Nycomed Gmbh Forme posologique a gout masque
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
CA2657093A1 (fr) 2006-07-07 2008-01-10 Steven P. Govek Inhibiteurs de pde4 a base de composes d'heteroaryle bicyclique
USD580547S1 (en) * 2007-07-31 2008-11-11 Nycomed Gmbh Tablet
JP5271070B2 (ja) 2008-12-24 2013-08-21 エスアイアイ・プリンテック株式会社 ヘッドチップ、液体噴射ヘッド及び液体噴射装置
US20120052122A1 (en) 2010-08-26 2012-03-01 Nycomed Gmbh Treatment Of Chronic Obstructive Pulmonary Disease With Phosphodiesterase-4 Inhibitor
WO2012154563A1 (fr) 2011-05-06 2012-11-15 Glaxosmithkline Llc Formulations de paracétamol à libération prolongée
BR112014021935A2 (pt) 2012-03-05 2019-09-24 Gilead Calistoga Llc formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure

Also Published As

Publication number Publication date
NO332844B1 (no) 2013-01-21
KR20100103729A (ko) 2010-09-27
PT2258394E (pt) 2013-07-23
NZ535197A (en) 2006-11-30
UA84266C2 (uk) 2008-10-10
ES2424634T3 (es) 2013-10-07
CN102764242B (zh) 2016-09-07
PL370595A1 (en) 2005-05-30
US20140031397A1 (en) 2014-01-30
KR101253033B1 (ko) 2013-04-11
MXPA04005759A (es) 2004-09-10
CA2475923C (fr) 2013-06-18
ECSP045238A (es) 2004-09-28
US20060269600A1 (en) 2006-11-30
PE20030823A1 (es) 2003-10-11
AR038527A1 (es) 2005-01-19
DK1478399T3 (da) 2012-06-25
CN1635909A (zh) 2005-07-06
SI2258394T1 (sl) 2013-09-30
ES2384378T3 (es) 2012-07-04
ME00566B (fr) 2011-12-20
US20130345265A1 (en) 2013-12-26
AU2003206924A1 (en) 2003-09-09
DK2258394T3 (da) 2013-08-19
NO20043904L (no) 2004-11-11
US20150290179A1 (en) 2015-10-15
JP2005517724A (ja) 2005-06-16
JP4163120B2 (ja) 2008-10-08
EP1478399A1 (fr) 2004-11-24
US20140031396A1 (en) 2014-01-30
US7951397B2 (en) 2011-05-31
CN102764242A (zh) 2012-11-07
US20150290180A1 (en) 2015-10-15
EP1478399B1 (fr) 2012-03-21
RS73604A (sr) 2007-02-05
TNSN04124A1 (en) 2007-03-12
US20110060016A1 (en) 2011-03-10
AU2003206924B2 (en) 2008-11-13
CN1635909B (zh) 2012-09-05
TWI363636B (en) 2012-05-11
PL226401B1 (pl) 2017-07-31
KR20040084926A (ko) 2004-10-06
BR0307739A (pt) 2005-01-25
TW200303768A (en) 2003-09-16
US9468598B2 (en) 2016-10-18
KR101386843B1 (ko) 2014-04-17
US20110251244A1 (en) 2011-10-13
IS7410A (is) 2004-08-18
PT1478399E (pt) 2012-05-30
IL237196A0 (en) 2015-03-31
ATE550038T1 (de) 2012-04-15
WO2003070279A1 (fr) 2003-08-28
CY1114210T1 (el) 2016-08-31
HK1077752A1 (en) 2006-02-24
US20050159492A1 (en) 2005-07-21
GEP20074079B (en) 2007-03-26
EP2258394B1 (fr) 2013-05-15
IL162843A0 (en) 2005-11-20
US8431154B2 (en) 2013-04-30
CY1112811T1 (el) 2016-02-10
ME00566A (en) 2011-12-20
EP2258394A1 (fr) 2010-12-08
US20150290178A1 (en) 2015-10-15
US20130131123A1 (en) 2013-05-23
SI1478399T1 (sl) 2012-07-31
EA200401019A1 (ru) 2005-04-28
MY140561A (en) 2009-12-31
RS52548B (sr) 2013-04-30
CA2475923A1 (fr) 2003-08-28
IL162843A (en) 2015-03-31
EA008219B1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
MA27100A1 (fr) Forme posologique orale contenant un inhibiteur de type 4 de pde en tant qu'ingredient actif et du polyvinylpyrrolidone en tant qu'excipient
IL165065A0 (en) Pharmaceutical compositions containing roflumilastfor treatment of eye disease
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
LU91854I2 (fr) Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)
DE69206345D1 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
CO5590918A2 (es) Formulaciones
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
PT1251846E (pt) Taxanos com carbonato c-4
HUP0201284A2 (hu) Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
MXPA03010607A (es) Compuesto de carbapenem.
ATE399526T1 (de) Pharmazeutische und kosmetische formulierungen zur behandlung der nägel
BR0214780A (pt) Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste
ES2171749T3 (es) Composiciones farmaceuticas que contienen inhibidores de la agregacion de plaquetas.
BR0113055A (pt) Preparação sólida altamente absorvìvel
FR2878443B1 (fr) Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation
AR036587A1 (es) Medicamento para el tratamiento terapeutico o preventivo de la tuberculosis que comprende un derivado de eritromicina